Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use

Current Medical Research and Opinion

Volumn 29, Issue 1, 2013, Pages 85-92

  Li, Wanying ^a   Sasso, Eric H ^a   Emerling, Daniel ^b   Cavet, Guy ^a   Ford, Kerri ^a  

^a Crescendo Bioscience   (United States)

^b Biosimplify   (United States)

Author keywords

Biomarker; Blood test; Disease activity; Rheumatoid arthritis; Treatment decisions

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; ETODOLAC; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL PRACTICE; DECISION MAKING; DISEASE ACTIVITY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; METHOTREXATE; MIDDLE AGED;

EID: 84871368232     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.753042     Document Type: Article

References (37)

1. Lijmer JG, Leeflang M, Bossuyt PM. Proposals for a phased evaluation of medical tests. Med Decis Making 2009;29:E13-21
2. Mol BW, Lijmer JG, Evers JL, et al. Characteristics of good diagnostic studies. Semin Reprod Med 2003;21:17-25
3. Pearl WS. A hierarchical outcomes approach to test assessment. Ann Emerg Med 1999;33:77-84
4. Van den Bruel A, Cleemput I, Aertgeerts B, et al. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J Clin Epidemiol 2007;60:1116-22
5. Lee DW, Neumann PJ, Rizzo JA. Understanding the medical and nonmedical value of diagnostic testing. Value Health 2010;13:310-14
6. Fryback DG, Thornbury Jr. The efficacy of diagnostic imaging. Med Decis Making 1991;11:88-94
7. Guyatt GH, Tugwell PX, Feeny DH, et al. A framework for clinical evaluation of diagnostic technologies. CMAJ 1986;134:587-94
8. van der Schouw YT, Verbeek AL, Ruijs SH. Guidelines for the assessment of new diagnostic tests. Invest Radiol 1995;30:334-40
9. Simons WR, Rosenblatt LC, Trivedi DN. The economic consequences of rheumatoid arthritis: analysis of Medical Expenditure Panel Survey 2004, 2005, and 2006 data. J Occup Environ Med 2012;54:48-55
10. Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 2000;3:243-52
11. Bakker MF, Jacobs JW, Verstappen SM, et al. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66(Suppl 3):iii56-60
12. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90
13. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9
14. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9
15. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43
16. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2008;67:266-9
17. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9
18. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7
19. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100-8
20. Ringold S, Singer NG. Measures of disease activity in rheumatoid arthritis: a clinician's guide. Curr Rheumatol Rev 2008;4:259-65
21. Zatarain E, Strand V. Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials. Nat Clin Pract Rheumatol 2006;2:611-18
22. Pincus T. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 2008;66:216-23
23. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2
24. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
25. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958-67
26. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70:404-13
27. Eastman PS, Manning WC, Qureshi F, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal 2012; 70:415-24
28. Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012;71:1692-7
29. Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 2012; 64:1794-803
30. Crescendo Bioscience, Inc. Daily Sales Report data on file for 2012 publication of Decision Impact Study: 011-MA-01. TMF # 001
31. Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. The American Statistician 1998;52:119-26
32. Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010;40:2-14 e11
33. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69:380-6
34. Ranganath VK, Paulus HE, Onofrei A, et al. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol 2008;35:1966-71
35. Bossuyt PM, McCaffery K. Additional patient outcomes and pathways in evaluations of testing. Med Decis Making 2009;29:E30-8
36. van der Helm-van Mil AH, Knevel R, Cavet G, et al. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford) 2012;in press
37. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009;36: 1387-90